Cargando…
Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia
We have analyzed the long-term outcome and toxicities in 98 patients with high-risk acute myelogenous leukemia (AML) who were treated with autologous bone marrow transplantation (ABMT) and monitored for a median observation period of 11.67 years. Between 1983 and 1994, 98 patients in our institution...
Autores principales: | Abdallah, A, Egerer, G, Weber-Nordt, RM, Körbling, M, Haas, R, Ho, AD |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092354/ https://www.ncbi.nlm.nih.gov/pubmed/12105772 http://dx.doi.org/10.1038/sj.bmt.1703586 |
Ejemplares similares
-
Bone Marrow Immunity and Myelodysplasia
por: Lambert, Claude, et al.
Publicado: (2016) -
Interleukin-2 receptor β chain as a possible target for low doses of mafosfamide
por: Pukhalsky, A., et al.
Publicado: (1995) -
purgeR: inbreeding and purging in pedigreed populations
por: López-Cortegano, Eugenio
Publicado: (2021) -
Mafosfamide Boosts GMI-HBVac against HBV via Treg Depletion in HBV-Infected Mice
por: Lin, Qin, et al.
Publicado: (2023) -
Selective ALDH3A1 Inhibition
by Benzimidazole Analogues
Increase Mafosfamide Sensitivity in Cancer Cells
por: Parajuli, Bibek, et al.
Publicado: (2014)